Press Releases

02.02.2021

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS

01.27.2021

Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)

01.26.2021

Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

01.25.2021

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

01.22.2021

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

01.14.2021

Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults

01.12.2021

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

01.10.2021

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development ofmRNA-based Vaccines and Biotherapies

01.07.2021

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

01.05.2021

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference

01.04.2021

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

12.29.2020

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®